CETP Inhibition

New Approaches to HDL Inhibition

View teaching slides on mechanisms and clinical trials with CETP inhibitors

New Approaches to HDL modification	The Inhibition of Cholesterol Ester Transfer Protein
CETP Levels and CAD risk:	Rationale
RADIANCE 1 and 2 Study Designs	RADIANCE 1
RADIANCE 2	RADIANCE 1- Heterozygous FH Adverse Events (All Causality)
ILLUMINATE	ILLUMINATE: Long-term Outcomes in Patients With CHD or CHD Risk Equivalence
On Trial Lipid Levels By Study Month	Primary Endpoint ILLUMINATE: Time to First MCVE: Kaplan-Meier Plot
Scientific Case for Developing the CETP inhibitor Anacetrapib	Anacetrapib Dose Ranging Study
Effect of HDL from Anacetrapib-treated Patients (300 mg) on Cholesterol Efflux from Human Macrophages	Effect of Torcetrapib and Anacetrapib on Blood Pressure in Rhesus Monkeys
The Effect of Torcetrapib and Anacetrapib on Aldosterone Secretion from Primary Rat Adrenocortical Cells	Development Strategy for Anacetrapib
Anacetrapib Program Timelines	Phase II/III: DEFINE, The Anacetrapib Safety study